• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Cancer Stem Cells Toggle Molecular Switch to Evade Immune Response; Dual-Target Therapy Offers New Hope for Colorectal Cancer

Bioengineer by Bioengineer
August 5, 2025
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

blank

In a groundbreaking advancement for cancer immunotherapy, researchers from the School of Medicine at Zhejiang University have elucidated a novel mechanism by which colorectal cancer stem cells (CSCs) evade immune system attack. Published in the prestigious journal Science Bulletin, this study, led by Professor Jimin Shao, reveals how inflammatory signals, specifically the cytokine interleukin-6 (IL-6), drive heterogeneous intracellular signaling that enables CSCs to express immunosuppressive PD-L1 and circumvent immune-mediated clearance. These findings address a crucial obstacle in current immunotherapeutic resistance and offer innovative avenues for tailored combination treatments.

The research centers on the pivotal role of IL-6, a cytokine long recognized for its involvement in promoting PD-L1 expression in various cancers. While the induction of PD-L1 by IL-6 in non-cancer stem cells (non-CSCs) follows the canonical JAK-STAT3 pathway, this study uncovers a strikingly divergent signaling route operating in CSCs. In differentiated cancer cells, IL-6 engagement leads to phosphorylation at the Y705 residue and acetylation at K685 of STAT3, facilitating the formation of a transcriptionally active STAT3-FRA1 complex that directly binds promoter regions of CD274, the gene encoding PD-L1. This classical cascade promotes PD-L1 transcription and contributes to immune checkpoint activation.

Contrastingly, colorectal CSCs undergo a radical signaling switch, wherein IL-6 triggers PI3K-AKT-ZEB1 axis activation instead of STAT3 phosphorylation. This signaling rerouting bypasses the standard JAK-STAT3 transcriptional machinery, actively recruiting the epithelial-mesenchymal transition (EMT) transcription factor ZEB1 to the CD274 promoter. Notably, ZEB1’s DNA binding site overlaps with that of FRA1, suggesting competitive binding dynamics that favor immune evasion pathways specific to CSCs. The application of LY294002, a selective PI3K inhibitor, effectively abrogates PD-L1 induction exclusively in CSCs, underscoring the mechanistic specificity of this alternative pathway.

.adsslot_f5FZz7MJau{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_f5FZz7MJau{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_f5FZz7MJau{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Delving into the molecular underpinnings of this signaling divergence, the team identified the enhanced activity of SHP2 phosphatase within CSCs as a key factor. SHP2 attenuates IL-6-mediated JAK-STAT3 signaling, thereby facilitating a redirection towards the PI3K-AKT cascade. This phosphatase-mediated rheostat function effectively transforms IL-6 signaling outcomes and reinforces the CSC’s capacity for immune escape through elevated PD-L1 expression. The competitive binding of ZEB1 versus the STAT3-FRA1 complex on the CD274 promoter further consolidates the dominance of this CSC-specific immunosuppressive program.

In a translational leap, the researchers validated these mechanistic insights within a cohort of 70 colorectal cancer patient samples. Tumors characterized by elevated IL-6 levels demonstrated a higher prevalence of PD-L1-positive, ZEB1-expressing CSCs accompanied by a notable depletion of cytotoxic T lymphocytes, indicating an immunosuppressive tumor microenvironment shaped by the novel signaling axis. These patient-derived data reinforce the clinical relevance of the discovered pathways and hint at biomarkers indicative of immune evasion and therapeutic resistance.

The therapeutic implications of these discoveries were probed in murine models genetically humanized for IL-6 expression. Strikingly, monotherapies targeting either the PI3K or STAT3 pathways, or immune checkpoint blockade alone, produced limited tumor regression. However, a triple combination regimen encompassing a PI3K inhibitor, a STAT3 inhibitor, and anti-PD-L1 antibodies induced profound tumor shrinkage. This combinatorial strategy simultaneously obstructs diverse escape routes exploited by CSCs and non-CSCs while rejuvenating T-cell-mediated anti-tumor immunity, exemplifying a precision medicine paradigm.

Professor Jimin Shao, the study’s corresponding author, emphasizes the potency of this integrated approach: “By simultaneously dismantling both IL-6-driven immunosuppressive signaling pathways, we effectively erode the protective barrier cancer stem cells construct against immune attack.” He further suggests the implementation of tumor or blood-based diagnostics measuring IL-6 and PD-L1 levels as predictive tools to stratify patients likely to benefit from such targeted combination therapies, a step toward personalized oncology.

The complexity of immune evasion in colorectal cancer is hence unveiled as a dynamic interplay of cellular heterogeneity and context-dependent signaling rewiring. This study highlights the transformative effect of post-translational modifications — phosphorylation and acetylation of STAT3 — in dictating transcriptional partnerships and gene expression programs in differentiated cancer cells, while uncovering how protein activity modulation via SHP2 shapes alternative transcription factor engagement in CSCs. Such mechanistic depth extends our molecular understanding of tumor immunobiology.

Moreover, the identification of ZEB1 as a pivotal transcriptional regulator of CD274 in CSCs broadens the functional repertoire of EMT-associated factors beyond their canonical roles in metastasis and invasion. The bridging of oncogenic signaling with immune checkpoint regulation underscores an intricate nexus between tumor plasticity and immune suppression, reframing EMT not only as a driver of phenotypic cellular transitions but also as a modulator of tumor immune landscapes.

The research team at Zhejiang University continues to validate these biomarkers and signaling pathways in extensive clinical cohorts, aiming to translate laboratory insights into effective therapeutic regimens. Their findings present a compelling case for combination immunotherapies tailored to cellular context and signaling heterogeneity within tumors, potentially reshaping clinical management strategies for colorectal cancer patients resistant to conventional single-modality treatments.

This study exemplifies the critical need to dissect cellular and molecular diversity within tumors to unravel mechanisms underpinning immunotherapy resistance. As the field progresses, such integrative approaches that map distinct signaling networks in subpopulations of cancer cells will pave the way for refining immune checkpoint blockade and overcoming tumor immune escape, ultimately improving patient outcomes.

By delineating an IL-6-induced STAT3-to-PI3K signaling switch that drives ZEB1-dependent PD-L1 expression, this work not only fills a vital knowledge gap but also provides a beacon for designing next-generation combination therapies that simultaneously target the multifaceted immune evasion tactics of colorectal cancer. Its implications reverberate through both fundamental cancer biology and clinical translational science, heralding a new chapter in combating one of the deadliest malignancies worldwide.

Subject of Research: Immuno-oncology, colorectal cancer stem cells, IL-6 signaling, immune evasion mechanisms, PD-L1 regulation.

Article Title: How IL-6 Signaling Rewires Immune Checkpoint Control in Colorectal Cancer Stem Cells

Web References: http://dx.doi.org/10.1016/j.scib.2025.07.013

Image Credits: ©Science China Press

Keywords: Colorectal cancer, cancer stem cells, IL-6, PD-L1, immune evasion, JAK-STAT3 pathway, PI3K-AKT pathway, ZEB1, tumor microenvironment, immunotherapy resistance, SHP2 phosphatase, EMT transcription factors

Tags: cancer stem cellscolorectal cancer therapycytokine influence on tumor immunitydual-target cancer treatmentImmune Evasion Mechanismsimmunotherapy resistance challengesinterleukin-6 role in cancernovel cancer treatment approachesPD-L1 immune checkpointPI3K-AKT signaling in CSCssignaling pathways in cancerSTAT3 transcriptional regulation

Share12Tweet8Share2ShareShareShare2

Related Posts

Attachment Styles Link Emotions to Gaming Disorder Risks

Attachment Styles Link Emotions to Gaming Disorder Risks

August 5, 2025
blank

Chronic Illness Links to Kids’ Play and Mental Health

August 5, 2025

Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

August 5, 2025

Hidden and Overt Weight Bias in Healthcare Professionals

August 5, 2025

POPULAR NEWS

  • blank

    Neuropsychiatric Risks Linked to COVID-19 Revealed

    73 shares
    Share 29 Tweet 18
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    46 shares
    Share 18 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Trematode Species Found in Mediterranean Cardinal Fish

Predator Traits Shape Nanoplastic Uptake in Aquatics

Attachment Styles Link Emotions to Gaming Disorder Risks

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.